Investors sentiment decreased to 0.88 in 2017 Q2. Its down 0.16, from 1.04 in 2017Q1. It dropped, as 81 investors sold BIIB shares while 321 reduced holdings. 78 funds opened positions while 277 raised stakes. 180.66 million shares or 1.01% less from 182.50 million shares in 2017Q1 were reported. Roundview Cap Ltd Com reported 1,301 shares stake. Eqis Capital Mgmt accumulated 4,182 shares. Hudock Grp Limited Liability Corporation reported 0.01% stake. Welch And Forbes Ltd Liability Corp holds 0.06% or 7,899 shares in its portfolio. Hartford Mngmt reported 0.01% in Biogen Inc. (NASDAQ:BIIB). Busey holds 0.59% or 15,825 shares. The New York-based Morgan Stanley has invested 0.09% in Biogen Inc. (NASDAQ:BIIB). Pointstate Capital LP reported 0.46% in Biogen Inc. (NASDAQ:BIIB). Amer Retail Bank accumulated 38 shares. Sentinel Asset Mngmt stated it has 0.49% of its portfolio in Biogen Inc. (NASDAQ:BIIB). Swedbank reported 578,425 shares. Atlanta Capital Gp, Georgia-based fund reported 7,615 shares. Fifth Third National Bank reported 76,529 shares. Art Advisors Ltd Llc reported 0.17% stake. Loomis Sayles And Com LP stated it has 61,508 shares or 0.04% of all its holdings.
Mufg Americas Holdings Corp decreased its stake in Biogen Inc (BIIB) by 40.82% based on its latest 2017Q2 regulatory filing with the SEC. Mufg Americas Holdings Corp sold 13,511 shares as the company’s stock declined 13.45% while stock markets rallied. The institutional investor held 19,584 shares of the biological products (no diagnostic substances) company at the end of 2017Q2, valued at $5.32 million, down from 33,095 at the end of the previous reported quarter. Mufg Americas Holdings Corp who had been investing in Biogen Inc for a number of months, seems to be less bullish one the $69.16 billion market cap company. The stock increased 0.33% or $1.07 during the last trading session, reaching $327.02. About 866,722 shares traded. Biogen Inc. (NASDAQ:BIIB) has risen 4.94% since December 20, 2016 and is uptrending. It has underperformed by 11.76% the S&P500.
Mufg Americas Holdings Corp, which manages about $3.10B US Long portfolio, upped its stake in Ishares Tr (IVW) by 39,194 shares to 235,998 shares, valued at $32.30M in 2017Q2, according to the filing. It also increased its holding in Ishares Tr (AGG) by 41,166 shares in the quarter, for a total of 177,442 shares, and has risen its stake in Vanguard Index Fds (VOO).
Analysts await Biogen Inc. (NASDAQ:BIIB) to report earnings on January, 25. They expect $5.52 EPS, up 9.52 % or $0.48 from last year’s $5.04 per share. BIIB’s profit will be $1.17 billion for 14.81 P/E if the $5.52 EPS becomes a reality. After $6.31 actual EPS reported by Biogen Inc. for the previous quarter, Wall Street now forecasts -12.52 % negative EPS growth.
More notable recent Biogen Inc. (NASDAQ:BIIB) news were published by: Bostonglobe.com which released: “At a UMass lab, a eureka moment” on December 17, 2017, also Investorplace.com with their article: “Bet on Biogen Inc for Easy Profits Into the New Year” published on November 21, 2017, Fool.com published: “Biogen Inc. Buys Its Way Out of Competition” on November 27, 2017. More interesting news about Biogen Inc. (NASDAQ:BIIB) were released by: Finance.Yahoo.com and their article: “Biogen Inc (BIIB): Immense Growth Potential?” published on November 23, 2017 as well as Streetinsider.com‘s news article titled: “Biogen Inc.” with publication date: November 21, 2017.
Biogen Inc. (NASDAQ:BIIB) Ratings Coverage
Among 31 analysts covering Biogen Idec Inc. (NASDAQ:BIIB), 21 have Buy rating, 0 Sell and 10 Hold. Therefore 68% are positive. Biogen Idec Inc. has $450 highest and $268 lowest target. $349.72’s average target is 6.94% above currents $327.02 stock price. Biogen Idec Inc. had 92 analyst reports since July 23, 2015 according to SRatingsIntel. The firm has “Equal-Weight” rating by Morgan Stanley given on Wednesday, July 26. The stock has “Hold” rating by BMO Capital Markets on Monday, July 17. The rating was maintained by Raymond James with “Strong Buy” on Thursday, December 29. Robert W. Baird downgraded the stock to “Neutral” rating in Monday, July 27 report. The rating was maintained by Goldman Sachs with “Buy” on Tuesday, October 24. The stock of Biogen Inc. (NASDAQ:BIIB) has “Outperform” rating given on Friday, December 4 by Wells Fargo. The rating was maintained by Bernstein on Tuesday, November 28 with “Buy”. The firm has “Hold” rating given on Tuesday, July 25 by Cantor Fitzgerald. Jefferies maintained the shares of BIIB in report on Wednesday, October 5 with “Hold” rating. The rating was initiated by Citigroup with “Buy” on Thursday, February 25.